TATUM-T Drug Patent Profile

When do Tatum-t patents expire, and what generic alternatives are available?

Tatum-t is a drug marketed by Gd Searle Llc and is included in one NDA.

The generic ingredient in TATUM-T is copper. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the copper profile page.

Summary for TATUM-T

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2869
Patent Applications:	2,000
DailyMed Link:	TATUM-T at DailyMed

US Patents and Regulatory Information for TATUM-T

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gd Searle Llc	TATUM-T	copper	INTRAUTERINE DEVICE;INTRAUTERINE	018205-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for TATUM-T

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gd Searle Llc	TATUM-T	copper	INTRAUTERINE DEVICE;INTRAUTERINE	018205-001	Approved Prior to Jan 1, 1982	RE28399
Gd Searle Llc	TATUM-T	copper	INTRAUTERINE DEVICE;INTRAUTERINE	018205-001	Approved Prior to Jan 1, 1982	3,563,235
Gd Searle Llc	TATUM-T	copper	INTRAUTERINE DEVICE;INTRAUTERINE	018205-001	Approved Prior to Jan 1, 1982	4,040,417
Gd Searle Llc	TATUM-T	copper	INTRAUTERINE DEVICE;INTRAUTERINE	018205-001	Approved Prior to Jan 1, 1982	3,803,308
Gd Searle Llc	TATUM-T	copper	INTRAUTERINE DEVICE;INTRAUTERINE	018205-001	Approved Prior to Jan 1, 1982	3,783,861

International Patents for TATUM-T

See the table below for patents covering TATUM-T around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	941254	INTRAUTERINE CONTRACEPTIVE METHOD

TATUM-T Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of CAR T-Cell Therapy: A Comprehensive Overview

Introduction to CAR T-Cell Therapy

CAR T-cell therapy is a revolutionary form of immunotherapy that has transformed the treatment landscape for various types of cancer. This innovative approach involves modifying a patient’s own T cells to express a Chimeric Antigen Receptor (CAR) that targets specific proteins on cancer cells, enabling the immune system to recognize and destroy these cells more effectively.

Market Size and Growth Projections

The global CAR T-cell therapy market is experiencing rapid growth, driven by significant advancements in cell engineering and gene editing techniques. Here are some key projections:

• Global Market Size: The global CAR T-cell therapy market is expected to reach approximately USD 88.52 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 29.8% from 2023 to 2032. In 2023, the market size was valued at USD 8.44 billion[1][4].

• Regional Growth:

  • North America: This region dominated the market with a share of 39.80% in 2023, valued at USD 3.36 billion. It is expected to grow to USD 35.50 billion by 2032 at a CAGR of 29.9%[1].
  • Europe: Europe is expected to grow at the highest rate during the forecast period, with a market size projected to reach USD 25.82 billion by 2032 from USD 2.37 billion in 2023, at a CAGR of 30.3%[1].
  • Asia Pacific: The APAC region is projected to reach USD 18.65 billion by 2032 from USD 1.69 billion in 2023, growing at a CAGR of 30.5%[1].
  • LAMEA: This region is expected to reach USD 8.54 billion by 2032 from USD 1.01 billion in 2023, growing at a CAGR of 26.8%[1].

Key Drivers of Market Growth

Increasing Incidence of Cancer

The rising global incidence of cancer, particularly in developing markets, is a significant driver of the CAR T-cell therapy market. The increasing geriatric population, which is more vulnerable to cancer, further fuels this growth[1].

Advancements in Cell Engineering and Gene Editing

Developments in cell engineering and gene editing techniques are enhancing the accuracy and efficacy of CAR T-cell therapy. These advancements are expected to improve patient outcomes and drive market growth[1].

Government and Private Investments

Significant investments from government agencies, pharmaceutical corporations, and venture capital firms are driving the growth of the CAR T-cell therapy market. These investments support research, clinical trials, and the development of new therapies[4].

Market Segmentation

By Drug Type

The market is segmented based on drug types such as:

• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Brexucabtagene Autoleucel
• Others

The Tisagenlecleucel segment is expected to dominate the market due to its substantial clinical success[4].

By Indication

The market is categorized based on indications such as:

• Lymphoma
• Acute Lymphocytic Leukemia
• Others

The lymphoma segment dominated the global market in 2022 due to the high prevalence of lymphoma globally[1].

By End-Users

The market is segmented based on end-users such as:

• Hospitals
• Cancer Treatment Centers

Hospitals and cancer treatment centers are the primary end-users, with hospitals holding a significant share of the market[1].

Challenges and Limitations

High Cost of Therapy

One of the major challenges facing the CAR T-cell therapy market is the high cost of treatment. This cost barrier limits accessibility, especially in developing regions. Companies are working to streamline the production process to reduce costs[1].

Impact of COVID-19

The COVID-19 pandemic has had a mixed impact on the CAR T-cell therapy market. While it highlighted the importance of advanced treatments like CAR T-cell therapy, it also affected clinical trials and supply chains, slightly restricting market growth from earlier predictions[1].

Recent Developments and Trends

Clinical Trials and Research

The market is witnessing a surge in research and clinical trials, driven by the successful results of existing therapies. This has encouraged additional investment and advancement in the field[4].

Regulatory and Healthcare Infrastructure

Improving healthcare infrastructure, especially in Europe, and the rise in pharmaceutical and biotechnology investments are driving market growth. Regulatory support and growing awareness about CAR T-cell therapy are also key factors[1].

Key Players and Market Share

Major players in the CAR T-cell therapy market include:

• Bristol-Myers Squibb
• Johnson & Johnson
• Gilead Sciences
• Intellia Therapeutics
• Pfizer Inc.

These companies are contributing significantly to the market growth through their R&D activities and strong market presence[1].

Regional Insight

North America

North America dominated the market in 2023, driven by high R&D activities and the presence of key players. The region's strong healthcare infrastructure and regulatory support also contribute to its market leadership[1].

Europe

Europe is expected to grow at the highest rate during the forecast period due to a high prevalence of cancer, a large and diverse population, and improving healthcare infrastructure[1].

Future Outlook

The CAR T-cell therapy market is poised for significant growth, driven by ongoing advancements in technology, increasing investments, and rising demand for effective cancer treatments.

"The industry's optimism has been boosted by the successful results of these therapies, which has encouraged additional investment and advancement in this field."[4]

Key Takeaways

• The global CAR T-cell therapy market is projected to reach USD 88.52 billion by 2032, growing at a CAGR of 29.8% from 2023 to 2032.
• North America, Europe, and the Asia Pacific are the key regions driving market growth.
• The high cost of therapy and the impact of the COVID-19 pandemic are significant challenges.
• Advancements in cell engineering and gene editing, along with increasing investments, are key drivers of market growth.

FAQs

What is CAR T-cell therapy?

CAR T-cell therapy is an innovative form of immunotherapy that involves modifying a patient’s own T cells to express a Chimeric Antigen Receptor (CAR) designed to recognize specific proteins on cancer cells.

What is the projected market size of the CAR T-cell therapy market by 2032?

The global CAR T-cell therapy market is expected to reach approximately USD 88.52 billion by 2032.

Which region is expected to grow at the highest rate during the forecast period?

Europe is expected to grow at the highest rate during the forecast period due to a high prevalence of cancer, a large and diverse population, and improving healthcare infrastructure.

What are the main challenges facing the CAR T-cell therapy market?

The high cost of therapy and the impact of the COVID-19 pandemic on clinical trials and supply chains are significant challenges.

Which drug type is expected to dominate the market growth?

The Tisagenlecleucel segment is expected to dominate the market due to its substantial clinical success.

What are the key drivers of the CAR T-cell therapy market?

The key drivers include the increasing incidence of cancer, advancements in cell engineering and gene editing, and significant investments from government agencies, pharmaceutical corporations, and venture capital firms.

Sources

1. Biospace: "CAR T-Cell Therapy Market is Rising Rapidly at CAGR 29.8% by 2032"[1]
2. Randstad USA: "Tatum Provides Interim Financial Leadership for a Post-Acquisition"[2]
3. PubMed: "Shifting drug markets in North America - a global crisis in the making?"[3]
4. GlobeNewswire: "By 2034, CAR-T Cell Therapy Market Set to Soar USD 8.7 Billion at 1.80 CAGR"[4]
5. Fox News: "Tatum O'Neal's near-death experience caps life of drug addiction, abuse, volatile relationships"[5]